Major depression is associated with subjective wellbeing, increased mortality 1,2 and, more importantly for health care providers, increased health service utilization. [3] [4] [5] The weighted average prevalence of major depression in older people was 1.8% in an international systematic review, although estimates as high as 35% have been reported. 6 Little is known about the effectiveness of treatments for depressed older people in primary care. 7 More evidence exists concerning the management of depression in other settings, 8 yet a review of international studies (mostly conducted in Britain and the USA) suggests that only ~10% of depressed older people are referred to psychiatric services. 9 This latter group are likely to differ substantially from depressed primary care attenders by being more severely depressed. 10, 11 We have sought, therefore, to identify studies of treatments for depression in older people in primary care in order to summarize the current state of knowledge and to provide guidance for future studies in this area.
Index, and the references of studies we identified as well as those of other reviews of antidepressant treatment. Controlled clinical trials, randomized controlled trials, 'controlled before and after studies' and 'interrupted time series' studies were included if they were published between 1980 and June 1999 and the language of publication was English, French or German. We sought trials of cognitive and/or behavioural therapy, 12 interpersonal psychotherapy, 13, 14 'counselling', social support and drug treatment.
In addition, subjects had to be recruited from a sample of the general population or from primary care attenders. Studies were included if all subjects were over the age of 60 years. However, studies that were not elderly specific but included some subjects over the age of 60 were sought and analysed separately. Initial selection on all the above criteria was made by one of the authors.
Methodological quality criteria for inclusion
All included studies had to comply with the quality criteria for intervention studies published by the Cochrane Effective Practice and Organisation of Care Group. 15 The criteria pertinent to the retrieved studies were: relevant and interpretable data, concealed allocation of subjects, follow-up of at least 80-100% of randomized patients, a baseline measurement, a reliable primary outcome measure, protection against contamination, and blinded assessment of primary outcomes or use of an objective outcome measure. This review was, however, not carried out by members of the Cochrane Effective Practice and Organisation of Care Review Group but employed some of its methods.
Two reviewers, trained in the use of the quality criteria, read each study independently (and blind to the other's appraisal). They summarized the presented data and categorized the compliance of studies with the quality criteria (done, not clear, not done or do not know). They then compared their findings and discussed differences. Agreement on the accuracy of the factual information, the quality and the decision to include or exclude a study were made by consensus between the two reviewers. In general, studies were excluded if one of the quality criteria was classified as 'not done'. However, the actual method of randomization often was not stated. We therefore included studies that stated randomization without providing further detail.
Results
Seven studies of patients over the age of 60 years met all selection criteria. All were randomized controlled trials. Only two of them also met all methodological quality criteria and were therefore included in the review. Both investigated the effectiveness of psychiatric team care for patients with depressive symptoms or depression found among a population sample screened for depressive symptoms. Information about included and excluded studies is presented in Tables 1 and 2, respectively. We found no studies of psychological treatment, nor did we find any high quality studies of drug treatment in the studies restricted to older people. Studies of drug treatment that we did find were short (4-8 weeks) and excluded many patients with other illnesses, thus making any assessment of how treatment would perform under health service conditions (effectiveness) rather than ideal circumstances (efficacy) virtually impossible.
Exclusions commonly used in studies of antidepressants in older people are summarized in Table 3 to show the limited generalizability of drug trial results.
Given the extent of the evidence, only limited conclusions are possible. A flexible approach to the treatment of depression in older people led by a community psychiatric team can lead to the considerable improvement of 40-50% of those treated. Routine treatment in primary care only achieved ~25-30% improvement. The difference was probably largely due to the greater number of patients on antidepressant drug treatment in the intervention groups.
A total of eight studies that were not primarily of older people, but did include patients over the age of 60 years, met all selection criteria. All were randomized controlled trials of antidepressant drugs. Three of them also met all methodological quality criteria and were therefore included in the review. None of the eight studies investigated the effectiveness of psychotherapy.
The studies are also shown not because they allow specific conclusions to be drawn for the overall effectiveness of antidepressant treatment in older people but because they provide a fuller impression of the treatments used with older people even when they were not the focus of the study. Only one excluded study analysed results for subjects over 65 years separately. A metaanalysis of results was therefore impossible.
We did not analyse effect sizes in more detail because of this lack of separate analysis and the lack of comparability of patient groups between the two trials of older people alone.
In contrast to trials of psychiatric team care, the drug trials of antidepressant drugs with less representative participants and of younger patients achieved higher rates of improvement (54-81%). The most likely explanation would be the exclusion of patients with significant co-morbidity. It is also worth noting that 47% of patients treated with placebo improved over 6 months in the study of Malt et al., 16 probably reflecting the spontaneous improvement of some patients over the relatively long observation period as well as the placebo effect.
We cannot say on the basis of our review whether serotonin re-uptake inhibitors (SSRIs) should be used in preference to older antidepressants in the elderly. The high quality studies of community mental health team care did not provide a breakdown of specific treatments Family Practice-an international journal In addition to the common exclusions also excluded those whose MADRS score decreased by Ͼ20% during placebo treatment prior to randomization a Proportion improved represents either those with a 50% drop in scores on a depression screening tool or a move from case to non-case. used. Of the studies including some patients over the age of 60, only that of Malt 16 compared a tetracyclic antidepressant (mianserin) with an SSRI (sertraline) and placebo. Total drop-out from active treatment was 29% for the tetracyclic, 26% for the SSRI and 5% for placebo. In contrast, Ekselius et al. 17 compared two SSRIs in a slightly younger population with only about half the drop-out rates (10 and 15%). Subject selection rather than the nature of the drug may be the cause of the differences between studies of similar size and the same duration.
Discussion
The aim of this review was to evaluate critically the current evidence for treatment of depression in older people. We found a lack of good quality studies in this area as well as a concentration on treatment of severe depression with no allowance made for prior duration, previous episodes or additional morbidity. The focus on severe depression is understandable as researchers have reliable methods to identify severe depression. However, depressive symptoms below that level are much harder to classify meaningfully. They could represent the early or late stages of severe depression, reactions to upsetting life events or the response to adverse social circumstances. They could also be the effect of physical disease such as stroke. Older primary care patients with depressive symptoms also have more physical illness than their non-depressed peers. 18 As in major depression, the treating physician has to decide whether to consider depressive symptoms as a disorder in their own right or as the symptom of another illness. 19 A previous history of depression particularly before the age of 65 increases the likelihood of recurrence. 20 Age alone after adjustment for other known risk factors does not appear to make depression more likely. 21 In contrast, it has been debated whether older people are less depressed than younger age groups. 22, 23 However, it is clear that the inability to fulfil social roles resulting from physical disabilities is a major risk factor for depression in older people. [24] [25] [26] Ironically, this risk factor may be the reason why older people often are excluded from trials of potentially effective interventions for depression.
Older people take more medication on a regular basis, 27 thus increasing the likelihood of drug interactions and making contra-indications to the use of antidepressant drugs more likely. The need for other forms of treatment therefore becomes more pressing in this age group.
Improvements on placebo that were apparent in Malt's generally younger study population 16 may be less common in older people. A systematic review found that after 1 year, only 33% of patients were well compared with 21% who had died and another 33% who were still depressed. 28 Because of the protracted nature of late life depression, studies need to treat or at least follow-up participants for at least 6 months.
Studies to date that have compared SSRIs and older antidepressants have been efficacy studies. We still need studies showing us how newer antidepressant drugs would perform specifically for older patients with minimal exclusions. Such studies might take the same flexible approach as Waterreus' and Banerjee's studies 29, 30 but use exclusively SSRIs in one group and older antidepressants in the other group.
Cognitive and behavioural psychotherapy can improve severe depression in depressed psychiatric in-and outpatients. Interpersonal psychotherapy has been tested successfully in maintenance treatment of recurrent severe depression. [31] [32] [33] [34] Cognitive behavioural therapy has also been shown to be effective when delivered to psychiatric out-patients as an outreach service. 35 Consequently, if psychotherapy was given to primary care patients, it should only be offered to those with major depression. This will require some formal psychiatric assessment.
Counselling was included in our review because it is widely available in UK primary care. It does not describe any specific psychotherapeutic approach but individual approaches to helping clients by counsellors with different backgrounds and with or without formal qualifications. 36 A recent review of the effectiveness of counselling for major depression in adults under the age of 65 concluded that counselling was not effective in the treatment of major depression on current evidence 37 and did not recommend its use for that purpose. However, it is also tremendously popular with the general public in Britain, with 90% of a representative sample considering it as effective for depression and only 60% thinking the same about antidepressants. 38 Treatments for late life depression 325 The benefits of all forms of treatment are much less clear for patients with milder forms of depression whose weighted average prevalence in the community is 9.8%. 6 It is also found more commonly in primary care. Only a third of adults under 65 years treated by primary care physicians in London reached Hamilton Depression Scale scores commonly used to select depressed individuals for inclusion into drug trials. 11 It has been suggested that by limiting research to uncomplicated major depressive disorder, tested treatments may only apply to Ͻ15% of depressed primary care patients. 7 Consequently, it is likely that primary care physicians currently are treating many depressed patients for whom there is no evidence that antidepressants are more effective than placebo.
We do not deny the obstacles confronting researchers who wish to study treatment strategies for depression in primary care. Only 11% of older people living in the community and screened as depressed would agree to take antidepressant medication as part of a trial. 3 GPs too need to be convinced of the importance of evaluating interventions for adequate sample sizes to be achieved. In one study in the UK, only 10% of randomly selected practices were willing to take part. 40 Losses to follow-up may be ~10% over 1 year especially if those over 80 years are included. Although the prevalence of dementia in 60-to 64-year-olds is only ~1%, in 95-to 99-year-olds 35% suffer from the condition. Test thresholds of case finding instruments change in the presence of mild dementia, 41 and an assessment may become very difficult when it is severe. The design of future trials needs to address these problems to ensure that health care professionals can base their treatment on better evidence of effectiveness.
The alternative, chosen by some studies, of undertaking a population survey increases the numbers of eligible individuals but goes beyond the self-referral or case finding practised in primary care. Consequently, those studies tell us more about the burden of disease than the effectiveness of interventions in a primary care setting.
The natural history of depression is very variable. The positive predictive value of a variety of screening tools in primary care attenders was ~30% in one study of emergency primary care attenders. 42 Only three out of 10 individuals identified by those screening tools as probably depressed, were actually depressed. For those reasons, if none other, screening is unlikely to be adopted as a routine measure.
On the basis of this systematic review, we would recommend that more research needs to be undertaken into the effectiveness of all forms of treatment of depression, both major and less severe, in older people by GPs. More evidence is needed about the effectiveness of psychological treatment for depressed older patients in primary care settings.
